{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:36:45Z","timestamp":1760297805885},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study describes the first phase II study of S-1, a novel oral fluoropyrimidine, in a non-Japanese Asian population with advanced gastric cancer. S-1 was administered twice daily for 28 days every 6 weeks. A pharmacokinetic study was performed on day 28 of cycles 1 and 3. Genomic DNA from peripheral mononuclear cells was analyzed using a cDNA microarray-based comparative genomic hybridization (CGH) method. Thirty-one patients were initially given a dose of 35 mg\/m2 twice daily (bid) (group 1); then, the protocol was amended by increasing the dose to 40 mg\/m2 bid for an additional 31 patients (group 2) because of good tolerability to S-1. The overall response rate was 19.3% (95% confidence interval, 9.2%\u201329.5%). Over a median follow-up duration of 265 days, the median time to progression and overall survival time were 126 and 264 days, respectively. The 1-year survival rate was 34%. There was no grade 4 toxicity and the major adverse event was anemia. Pharmacokinetic parameters were similar to those of the previous Japanese reports. Microarray CGH identified 18 genes with copy number changes that were associated with hemoglobin reduction with S-1 treatment. A logistic regression analysis, integrating one clinical parameter (initial hemoglobin level) combined with three genetic copy number variations (HIST1H2BL, C10orf127, and XPNPEP2), provided a predictive model for the development of severe hemoglobin reduction. In conclusion, this study showed the feasibility of using S-1 at 35 mg\/m2 bid in gastric cancer. We suggest that the pharmacogenomic markers identified in this study may be potential candidates for predicting anemia after S-1 treatment.<\/jats:p>","DOI":"10.1634\/theoncologist.12-5-543","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T23:01:52Z","timestamp":1179961312000},"page":"543-554","source":"Crossref","is-referenced-by-count":26,"title":["Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations"],"prefix":"10.1093","volume":"12","author":[{"given":"Hei-Cheul","family":"Jeung","sequence":"first","affiliation":[{"name":"a Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[{"name":"a Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea"},{"name":"b Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea"},{"name":"c Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon Kyo","family":"Kim","sequence":"additional","affiliation":[{"name":"d Department of Internal Medicine, St. Vincent's Hospital, The Catholic University, Suwon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Young","family":"Lim","sequence":"additional","affiliation":[{"name":"e Department of Hematology-Oncology, Ajou University School of Medicine, Suwon,Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samyong","family":"Kim","sequence":"additional","affiliation":[{"name":"f Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si Young","family":"Kim","sequence":"additional","affiliation":[{"name":"g Department of Internal Medicine, Kyunghee University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jeong","family":"Gong","sequence":"additional","affiliation":[{"name":"h Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Hee","family":"Park","sequence":"additional","affiliation":[{"name":"a Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea"},{"name":"b Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joong Bae","family":"Ahn","sequence":"additional","affiliation":[{"name":"a Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea"},{"name":"c Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hoon","family":"Noh","sequence":"additional","affiliation":[{"name":"a Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea"},{"name":"b Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Cheol","family":"Chung","sequence":"additional","affiliation":[{"name":"a Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea"},{"name":"b Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea"},{"name":"c Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,5,1]]},"reference":[{"key":"2021122208300799400_R1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","article-title":"Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer","volume":"72","author":"Murad","year":"1997","journal-title":"Cancer"},{"key":"2021122208300799400_R2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","article-title":"Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer","volume":"8","author":"Glimelius","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122208300799400_R3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00042737-200403000-00003","article-title":"Systemic treatment of gastric cancer","volume":"16","author":"Dickson","year":"2004","journal-title":"Eur J Gastroentrol Hepatol"},{"key":"2021122208300799400_R4","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/1097-0142(20010601)91:11<2016::AID-CNCR1227>3.0.CO;2-I","article-title":"Adjuvant 5-fluorouracil plus doxorubicin in D2\u20133 resected gastric carcinoma: 15-year experience in single institute","volume":"91","author":"Jeung","year":"2001","journal-title":"Cancer"},{"key":"2021122208300799400_R5","first-page":"2408","article-title":"[Low-dose methotrexate and sequential 5-FU treatment in advanced gastric cancer]","volume":"11","author":"Sasaki","year":"1984","journal-title":"Gan To Kagaku Ryoho"},{"key":"2021122208300799400_R6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2","article-title":"A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer","volume":"67","author":"Krook","year":"1991","journal-title":"Cancer"},{"key":"2021122208300799400_R7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000227702","article-title":"Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: An effective and low-toxic regimen for patients with poor general condition","volume":"54","author":"Hsu","year":"1997","journal-title":"Oncology"},{"key":"2021122208300799400_R8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2141.1998.00613.x","article-title":"Gastric cancer associated with acute disseminated intravascular coagulation: Successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin","volume":"100","author":"Yeh","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122208300799400_R9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","article-title":"Fluorouracil in colorectal cancer \u2013 a tale of two drugs: Implication for biochemical modulation","volume":"15","author":"Sobrero","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122208300799400_R10","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2000.18.14.2772","article-title":"Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors","volume":"18","author":"Van Groeningen","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122208300799400_R11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00001813-200402000-00001","article-title":"The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors","volume":"15","author":"Schoffski","year":"2004","journal-title":"Anticancer Drugs"},{"key":"2021122208300799400_R12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000012032","article-title":"An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers","volume":"57","author":"Sugimachi","year":"1999","journal-title":"Oncology"},{"key":"2021122208300799400_R13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000012099","article-title":"Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer","volume":"58","author":"Koizumi","year":"2000","journal-title":"Oncology"},{"key":"2021122208300799400_R14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","article-title":"Late phase II study of novel oral fluoropyrimidine anticancer drugs S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients","volume":"34","author":"Sakata","year":"1998","journal-title":"Eur J Cancer"},{"key":"2021122208300799400_R15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10120-004-0306-3","article-title":"Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer","volume":"8","author":"Nagashima","year":"2005","journal-title":"Gastric Cancer"},{"key":"2021122208300799400_R16","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0959-8049(03)00237-5","article-title":"Phase II trial with S-1 in chemotherapy-na\u00efve patients with gastric cancer. A trial performed by the EORTC early clinical studies group (ECSG)","volume":"39","author":"Chollet","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122208300799400_R17","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1200\/JCO.2005.06.006","article-title":"Just when you thought the fluorouracil debate was over: S-1 and gastric cancer","volume":"23","author":"Ilson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208300799400_R18","first-page":"134","article-title":"Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors","volume":"9","author":"Hoff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122208300799400_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2021122208300799400_R20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-4347(96)00429-X","article-title":"Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry","volume":"691","author":"Matsushima","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2021122208300799400_R21","first-page":"169","volume-title":"The Guide of Pharmacokinetics by Microcomputer","author":"Yamaoka","year":"1983"},{"key":"2021122208300799400_R22","first-page":"17","article-title":"The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization","volume":"13","author":"Seo","year":"2004","journal-title":"Int J Mol Med"},{"key":"2021122208300799400_R23","doi-asserted-by":"crossref","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","article-title":"Cluster analysis and display of genome-wide patterns","volume":"95","author":"Eisen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208300799400_R24","first-page":"261","article-title":"Systematic analysis of cDNA microarray-based CGH","volume":"17","author":"Park","year":"2006","journal-title":"Int J Mol Med"},{"key":"2021122208300799400_R25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/cncr.20277","article-title":"Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma","volume":"100","author":"Shirao","year":"2004","journal-title":"Cancer"},{"key":"2021122208300799400_R26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-002-0457-z","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function","volume":"50","author":"Ikeda","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122208300799400_R27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jjco\/hyh067","article-title":"A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy","volume":"34","author":"Takahashi","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"2021122208300799400_R28","first-page":"2000","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug","volume":"5","author":"Hirata","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122208300799400_R29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002800000195","article-title":"UFT-induced haemolytic anemia","volume":"47","author":"Zurita Saavedra","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122208300799400_R30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/1097-0142(19890815)64:4<793::AID-CNCR2820640404>3.0.CO;2-8","article-title":"5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer","volume":"64","author":"Jabboury","year":"1989","journal-title":"Cancer"},{"key":"2021122208300799400_R31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01213011-200505000-00004","article-title":"Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes","volume":"15","author":"Innocenti","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"2021122208300799400_R32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/00498259609046718","article-title":"Ethnic related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations","volume":"26","author":"Shimada","year":"1996","journal-title":"Xenobiotica"},{"key":"2021122208300799400_R33","first-page":"685","article-title":"Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer","volume":"14","author":"Kusumoto","year":"1988","journal-title":"Eur J Surg Oncol"},{"key":"2021122208300799400_R34","first-page":"4086","article-title":"Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay","volume":"42","author":"Schlag","year":"1982","journal-title":"Cancer Res"},{"key":"2021122208300799400_R35","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0959-8049(01)00187-3","article-title":"UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)\/European Organization for Research Treatment of Cancer (EORTC) phase II trial","volume":"37","author":"Ravaud","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122208300799400_R36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00001813-200602000-00016","article-title":"Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer","volume":"17","author":"Sakamoto","year":"2006","journal-title":"Anticancer Drugs"},{"key":"2021122208300799400_R37","first-page":"909","volume-title":"Cancer: Principles and Practice of Oncology","author":"Pisters","year":"2005","edition":"Seventh Edition"},{"key":"2021122208300799400_R38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0009-9236(03)00090-0","article-title":"Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro","volume":"74","author":"Yoshida","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2021122208300799400_R39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1365-2125.2000.00234.x","article-title":"Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy","volume":"50","author":"Canaparo","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2021122208300799400_R40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.bjc.6603468","article-title":"A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens","volume":"95","author":"Jeung","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122208300799400_R41","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1038\/sj.onc.1206958","article-title":"Pharmacogenomics: Road to anticancer therapeutics nirvana?","volume":"22","author":"Desai","year":"2003","journal-title":"Oncogene"},{"key":"2021122208300799400_R42","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V88.5.1594.1594","article-title":"Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells","volume":"88","author":"Olweus","year":"1996","journal-title":"Blood"},{"key":"2021122208300799400_R43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase \u2013 the stem cell factor receptor","volume":"337","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122208300799400_R44","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0731830100","article-title":"Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis","volume":"100","author":"Shim","year":"2003","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-5-543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-5-543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/5\/543\/41835005\/oncolo_12_5_543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/5\/543\/41835005\/oncolo_12_5_543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T14:26:08Z","timestamp":1640183168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/5\/543\/6410500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,5,1]]},"published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-5-543","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,5,1]]},"published":{"date-parts":[[2007,5,1]]}}}